An experimental cannabis-based drug has successfully treated children with a rare form of severe epilepsy in a keenly anticipated clinical trial, more than doubling the value of its maker GW Pharmaceuticals.
The study of GW’s Epidiolex in Dravet syndrome is the first of four final-stage Phase III epilepsy trials, with results expected this year, that the drugmaker hopes will confirm the therapeutic benefits of cannabinoids, the active ingredients found in marijuana.
GW said on Monday the 120-patient trial showed patients taking Epidiolex achieved a median reduction in monthly convulsive seizures of 39 percent compared with a reduction on placebo of 13 percent.
The difference was highly statistically significant and optimism about the drug’s future sales sent shares in GW up 125 percent by 1230 GMT.
Our 4th of July Super Sale has been extended! Get double Patriot Points and free shipping on the hottest items!